Modality
Gene Editing
MOA
BCMA ADC
Target
TIGIT
Pathway
PI3K/AKT
RSVHCCMCC
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
~Apr 2018
→ ~Jul 2019
NDA/BLA
~Oct 2019
→ ~Jan 2021
Approved
Apr 2021
→ Jul 2028
ApprovedCurrent
NCT07892909
1,811 pts·MCC
2025-01→2026-03·Not yet recruiting
NCT08194631
1,907 pts·RSV
2022-03→2026-07·Not yet recruiting
NCT08241123
1,179 pts·RSV
2021-04→2028-07·Recruiting
4,897 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-03-133w agoPh3 Readout· MCC
2026-07-133mo awayPh3 Readout· RSV
2028-07-012.3y awayPh3 Readout· RSV
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Recruit…
Approved
Not yet…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-03-13 · 3w ago
MCC
Ph3 Readout
2026-07-13 · 3mo away
RSV
Ph3 Readout
2028-07-01 · 2.3y away
RSV
RecruitingNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07892909 | Approved | MCC | Not yet recr... | 1811 | SeizFreq |
| NCT08194631 | Approved | RSV | Not yet recr... | 1907 | EASI-75 |
| NCT08241123 | Approved | RSV | Recruiting | 1179 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |